AKYNZEO Drug Patent Profile

Which patents cover Akynzeo, and what generic alternatives are available?

Akynzeo is a drug marketed by Helsinn Hlthcare and is included in two NDAs. There are twenty-two patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in AKYNZEO is fosnetupitant chloride hydrochloride; palonosetron hydrochloride. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosnetupitant chloride hydrochloride; palonosetron hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Akynzeo

Akynzeo was eligible for patent challenges on April 19, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 23, 2032. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for AKYNZEO

US Patents:	22
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Clinical Trials:	11
Patent Applications:	149
Drug Prices:	Drug price information for AKYNZEO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for AKYNZEO
What excipients (inactive ingredients) are in AKYNZEO?	AKYNZEO excipients list
DailyMed Link:	AKYNZEO at DailyMed

See drug prices for AKYNZEO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AKYNZEO

Constraining patent/regulatory exclusivity:

9,951,016

NDA:

205718

Dosage:

CAPSULE;ORAL

Constraining patent/regulatory exclusivity:

9,908,907

NDA:

210493

Dosage:

POWDER;INTRAVENOUS

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AKYNZEO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano	PHASE4
Helsinn Healthcare SA	Phase 2
Simon Williamson Clinic	Phase 2

See all AKYNZEO clinical trials

Pharmacology for AKYNZEO

Drug Class	Serotonin-3 Receptor Antagonist Substance P/Neurokinin-1 Receptor Antagonist
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Cytochrome P450 3A4 Inhibitors Neurokinin 1 Antagonists P-Glycoprotein Inhibitors Serotonin 3 Receptor Antagonists

Paragraph IV (Patent) Challenges for AKYNZEO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AKYNZEO	Solution in SDV	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	235 mg/0.25 mg per 20 mL	210493	1	2022-04-19

US Patents and Regulatory Information for AKYNZEO

AKYNZEO is protected by twenty-four US patents.

This potential generic entry date is based on patent 9,908,907.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes	9,908,907		Y	Y
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes	10,208,073
Helsinn Hlthcare	AKYNZEO	fosnetupitant chloride hydrochloride; palonosetron hydrochloride	SOLUTION;INTRAVENOUS	210493-002	May 27, 2020		RX	Yes	Yes	8,426,450		Y	Y

Expired US Patents for AKYNZEO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014	5,202,333
Helsinn Hlthcare	AKYNZEO	netupitant; palonosetron hydrochloride	CAPSULE;ORAL	205718-001	Oct 10, 2014	6,297,375

International Patents for AKYNZEO

When does loss-of-exclusivity occur for AKYNZEO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

Chile

China

Colombia

Costa Rica

Croatia

Cyprus

Denmark

Dominican Republic

Ecuador

Eurasian Patent Organization

European Patent Office

France

Georgia, Republic of

Guatemala

Hong Kong

Hungary

India

Israel

Japan

Jordan

Lithuania

Malaysia

Mexico

Moldova, Republic of

Montenegro

Morocco

Netherlands

New Zealand

Nicaragua

Peru

Philippines

Poland

Portugal

San Marino

Serbia

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Tunisia

Ukraine

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering AKYNZEO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2015323515
Canada	2960599
China	107001275

Supplementary Protection Certificates for AKYNZEO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0430190	CA 2005 00023	Denmark
0430190	91162	Luxembourg		91162, EXPIRES: 20151127
0430190	300194	Netherlands		300194, 20101127, EXPIRES: 20151126

Last updated: August 12, 2026

Akynzeo is a differentiated antiemetic combination of netupitant and palonosetron used to prevent acute and delayed chemotherapy-induced nausea and vomiting. Its commercial profile is stable but mature: the product benefits from convenient single-dose administration and broad guideline positioning, while generic aprepitant, generic palonosetron, competing NK1 antagonists, and payer price pressure limit expansion. Helsinn does not publicly disclose Akynzeo revenue as a standalone line item, so its financial trajectory must be assessed through product lifecycle, market access, licensing structure, and competitive erosion rather than reported product sales.

Akynzeo Market Dynamics, Patent Exclusivity, and Financial Trajectory

What is Akynzeo and how does it work?

Akynzeo combines two antiemetic mechanisms in one product:

Component	Pharmacologic class	Primary role
Netupitant	Neurokinin-1, or NK1, receptor antagonist	Controls delayed chemotherapy-induced nausea and vomiting
Palonosetron	5-HT3 receptor antagonist	Controls acute chemotherapy-induced nausea and vomiting

The oral capsule contains 300 mg of netupitant and 0.5 mg of palonosetron. The product is administered once before chemotherapy. The FDA approved Akynzeo capsules in October 2014 for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including highly emetogenic chemotherapy and anthracycline plus cyclophosphamide regimens.[1]

A parenteral formulation, fosnetupitant and palonosetron, was later developed to extend the franchise to patients unable to take oral medication. The FDA approved the intravenous formulation in 2018 under the Akynzeo brand.[2] In Europe, the product is authorized for prevention of acute and delayed nausea and vomiting associated with highly emetogenic and moderately emetogenic chemotherapy.[3]

How large is the Akynzeo market?

Akynzeo competes in the supportive-care market for chemotherapy-induced nausea and vomiting, or CINV. The addressable market is driven by oncology treatment volume rather than by the number of patients receiving chronic therapy. Revenue therefore depends on:

• Number of chemotherapy cycles administered.
• Use of highly emetogenic and moderately emetogenic regimens.
• Guideline adherence.
• Hospital and oncology-clinic formulary placement.
• Reimbursement for branded fixed-dose combinations.
• Conversion from multi-pill antiemetic regimens to single-dose products.

CINV prevention is a guideline-supported standard of care. Major guideline frameworks recommend combinations incorporating an NK1 antagonist, a 5-HT3 antagonist, and dexamethasone for patients receiving highly emetogenic chemotherapy. The combination can be supplemented with olanzapine depending on the regimen and clinical risk.[4]

Akynzeo’s commercial value is concentrated in treatment settings where convenience, delayed-emesis control, and predictable administration are important. It has less pricing power in formularies that substitute generic aprepitant and generic palonosetron as separate products.

How does Akynzeo compare with competing antiemetics?

Akynzeo competes against both branded combinations and low-cost generic components.

Product or regimen	Main active ingredient or combination	Commercial position
Akynzeo	Netupitant plus palonosetron	Fixed-dose oral and intravenous combination
Emend	Aprepitant	Originator NK1 antagonist; oral and intravenous competitors include generic versions
Cinvanti	Injectable aprepitant emulsion	IV NK1 antagonist
Fosaprepitant and generic fosaprepitant	Prodrug of aprepitant	Common hospital-based alternative
Aloxi and generic palonosetron	Palonosetron	5-HT3 component used separately
Varubi	Rolapitant	Alternative oral NK1 antagonist with limited commercial momentum
Generic aprepitant plus generic palonosetron	Separate NK1 and 5-HT3 agents	Main price-based substitute

Akynzeo’s principal clinical differentiation is consolidation. A physician or infusion center can prescribe one fixed-dose product rather than separate netupitant or aprepitant and palonosetron products. That advantage is strongest where adherence, administration time, and delayed CINV control matter.

The economic disadvantage is the branded combination price. Generic aprepitant and palonosetron allow payers to unbundle the regimen at lower acquisition cost. This creates a persistent ceiling on Akynzeo pricing, particularly in hospital outpatient departments and integrated delivery networks.

What is the FDA regulatory status of Akynzeo?

The FDA approved Akynzeo capsules in 2014 and the intravenous formulation in 2018. The product is regulated as a small-molecule fixed-dose combination rather than a biologic.[1,2]

Regulatory event	Approximate date	Significance
FDA approval of oral Akynzeo	October 2014	Established the U.S. fixed-dose combination
FDA approval of IV Akynzeo	2018	Expanded use to patients requiring parenteral administration
European authorization	2015	Established commercial access across European markets
Post-approval lifecycle activity	Ongoing	Supports route-of-administration and market-access expansion

The FDA label supports use before chemotherapy and covers both highly emetogenic chemotherapy and anthracycline plus cyclophosphamide regimens. The product is not a treatment for established nausea and vomiting after onset; it is administered prophylactically.[1]

What patents protect Akynzeo?

Akynzeo is protected by patents covering the fixed combination, pharmaceutical compositions, and related formulations. The key U.S. patent family has included the following patents associated with Akynzeo listings and product protection:

Patent	General subject matter	Reported protection profile
U.S. Patent No. 8,609,863	Netupitant and palonosetron pharmaceutical composition	Core combination protection
U.S. Patent No. 9,018,311	Combination composition and formulation claims	Follow-on composition protection
U.S. Patent No. 9,463,220	Additional fixed-dose combination claims	Follow-on protection
U.S. Patent No. 10,292,922	Pharmaceutical formulation and related claims	Later-expiring formulation protection
Additional IV-related patents	Fosnetupitant and parenteral formulations	Route-specific protection

The FDA Orange Book is the controlling source for current listed patents, pediatric exclusivity, and applicable patent expiration information.[5] Patent portfolios can include multiple expiration dates because composition, formulation, method-of-use, and pediatric protections do not necessarily end simultaneously.

When does Akynzeo lose U.S. exclusivity?

The earliest core U.S. patent protection has generally been associated with the 2030 period, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and the specific patent claims listed for the product.[5] Later formulation and IV patents may extend protection beyond the earliest core combination patent.

Akynzeo’s practical generic-entry date will depend on:

1. Which patents an ANDA applicant challenges.
2. Whether the applicant files a Paragraph IV certification.
3. Whether the patent holder files suit within the statutory period.
4. Whether the litigation triggers a 30-month stay.
5. Whether any listed patents are invalidated, narrowed, or not infringed.
6. Whether an ANDA applicant targets the oral product, the IV product, or both.

Patent expiry should therefore be assessed at the product-and-route level rather than through a single headline date.

What Orange Book status does Akynzeo have?

Akynzeo is an FDA-approved small-molecule product with Orange Book-listed patents. The Orange Book distinguishes the reference-listed drug from its patents and regulatory exclusivities.[5]

The principal regulatory risk is an ANDA for a generic oral fixed-dose combination. A generic developer may also pursue separate netupitant and palonosetron products, although a direct generic substitute would need to match the reference product’s active ingredients, strength, dosage form, route, and relevant labeling requirements.

The IV formulation presents a more complex development path because the applicant must address fosnetupitant, the prodrug formulation, intravenous administration, and any formulation-specific patents. This can reduce the number of technically credible competitors relative to the oral capsule.

Are Paragraph IV challenges threatening Akynzeo?

A Paragraph IV challenge is possible when an ANDA applicant certifies that a listed patent is invalid, unenforceable, or not infringed. Publicly available product information and FDA records establish the Orange Book patent framework, but a definitive assessment of current Paragraph IV activity requires case-level review of FDA litigation records, district court dockets, and ANDA litigation notices.

The likely sequence for Akynzeo is:

• Early development of an oral generic fixed-dose combination.
• Patent certifications against core combination patents.
• Potential litigation by the patent holder.
• A statutory 30-month stay if litigation is timely filed.
• Market entry before patent expiry only if the generic prevails, reaches settlement, or obtains a licensed launch date.

The absence of a widely visible generic launch before the core patent period supports the view that Akynzeo remains commercially protected in the United States. That protection is stronger for the branded combination than for its individual pharmacologic components, both of which face generic competition in other products.

What formulation patents protect Akynzeo?

Formulation protection is commercially important because netupitant and palonosetron must be delivered in a stable, bioavailable fixed-dose product. The relevant formulation strategy covers:

• Co-formulation of the NK1 antagonist and 5-HT3 antagonist.
• Oral capsule composition.
• Dose uniformity and stability.
• Intravenous fosnetupitant delivery.
• Compatibility and administration requirements for the parenteral product.

Formulation patents can delay a direct copy even after broad composition claims expire. Their strength depends on claim breadth and whether a generic can design around specific excipients, ratios, particle characteristics, or manufacturing steps.

The IV franchise may have a higher technical barrier than the oral capsule because it combines a prodrug, sterile manufacturing, injectable formulation requirements, and clinical bridging considerations. That barrier can support longer post-core-patent commercial protection even if the oral product faces earlier substitution.

What method-of-use patents protect Akynzeo?

Akynzeo’s principal method of use is prophylaxis of acute and delayed CINV associated with chemotherapy. Method-of-use patents may cover:

• Use before highly emetogenic chemotherapy.
• Use with anthracycline and cyclophosphamide regimens.
• Prevention of delayed nausea and vomiting.
• Particular dosing schedules or combination regimens.

Method-of-use claims are less effective against generic entry when physicians can prescribe the generic for a non-patented indication or when the applicant uses a Section VIII statement to carve out patented uses. Their commercial value depends on how tightly the labeled indication maps to the patented method and how effectively the reference sponsor can enforce induced-infringement claims.

Which companies commercialize or license Akynzeo?

Helsinn is the originator and principal rights holder associated with Akynzeo. The company has historically used regional licensing and commercialization partnerships rather than relying on a single global operating model.

Eisai has been associated with Akynzeo commercialization in the United States through a collaboration with Helsinn. Regional rights and distribution arrangements have changed across markets and over time, making territory-specific diligence necessary.[6]

The licensing structure affects financial performance in two ways:

1. Helsinn can recognize licensing income, milestones, supply revenue, or royalties without bearing all commercial costs.
2. Regional partners can improve access to hospital and oncology channels while reducing Helsinn’s direct sales infrastructure.

Because Helsinn is privately held and does not provide a public-company segment breakdown for Akynzeo, reported partner revenue does not provide a clean global product-sales figure.

What is Akynzeo’s financial trajectory?

Akynzeo’s standalone revenue is not publicly disclosed by Helsinn in a sufficiently granular way to establish a verified annual sales series. The product is included within Helsinn’s broader portfolio, which has included oncology and supportive-care medicines, but public corporate reporting does not consistently isolate Akynzeo sales by year.

The financial trajectory can be characterized in four phases:

Launch and adoption, 2014 to 2017

The oral product entered a market already familiar with NK1 and 5-HT3 antiemetic therapy. Initial uptake depended on the value of combining two active agents in one capsule. Adoption was supported by guideline alignment and the need to control delayed CINV.

Franchise expansion, 2018 to 2020

The IV formulation expanded the addressable patient population and gave Helsinn a second route of administration. This reduced dependence on oral dosing and improved the product’s relevance in infusion-center settings.

Mature branded phase, 2021 onward

The product entered a mature commercial phase characterized by repeat use in chemotherapy cycles, regional formulary negotiations, and competition from generic component regimens. Growth likely depends more on market share, route expansion, and geographic penetration than on rapid category expansion.

Pre-generic defense phase

As core patents approach the 2030 period, value shifts from volume growth to lifecycle management. The IV product, formulation patents, regulatory exclusivity, and partner agreements become more important. The commercial objective is to preserve price and delay substitution rather than maximize unprotected volume.

How much revenue is exposed to generic entry?

The direct revenue exposure cannot be calculated from public disclosures because Akynzeo sales are not separately reported. The economic exposure is nevertheless material within the relevant product franchise.

Generic entry would affect:

• Branded oral capsule volume.
• Net price after payer rebates.
• Hospital formulary positioning.
• Partner royalties and supply revenue.
• Prescribing of the fixed combination versus separate generic components.

The erosion pattern would likely be gradual rather than immediate if substitution is limited by physician preference, hospital protocols, and the technical difficulty of reproducing the combination. The oral product would face the earliest substitution risk. The IV product could retain a longer period of premium pricing if formulation and manufacturing patents remain enforceable.

How strong is the Akynzeo patent estate?

Akynzeo has a moderately strong patent estate for a mature small-molecule combination. Its strengths are:

• Multiple patents around the fixed-dose combination.
• Separate oral and IV product strategies.
• Technical formulation requirements.
• A product aligned with a defined oncology-supportive-care use.
• Partner distribution across multiple regions.

Its weaknesses are:

• Generic availability of the underlying therapeutic classes.
• Potential design-around options for formulation claims.
• Method-of-use enforcement limitations.
• Limited ability to maintain premium pricing where payers can use separate generic agents.
• Absence of biologic-style interchangeability barriers.

The estate is stronger against a direct copy of the fixed-dose combination than against therapeutic substitution.

What generic launch scenarios exist for Akynzeo?

Three launch scenarios are commercially relevant:

Scenario	Timing	Market effect
Patent-protected launch after core expiry	Around or after the earliest core patent expiration	Rapid price erosion in the oral product
At-risk launch after successful Paragraph IV challenge	Before patent expiry	Potential sharp revenue loss and damages litigation
Staggered entry by route	Oral entry first, IV entry later	Preserves part of the franchise through injectable protection

A licensed generic settlement could create an agreed launch date before the final patent expiration. Settlement terms are not a public feature of the Akynzeo commercial record at the level required to quantify an authorized-generic risk.

Does Akynzeo face biosimilar risk?

Akynzeo faces no biosimilar risk because it is a small-molecule drug, not a biologic. Its relevant competitive threats are ANDA generics, therapeutic substitutes, hospital formulary restrictions, and generic versions of aprepitant and palonosetron.

This distinction matters financially. Biosimilar entry often produces a slower, multi-source erosion curve governed by interchangeability, contracting, and physician adoption. Akynzeo’s risk is more conventional small-molecule substitution, with potentially faster price compression once a substitutable generic is approved.

What litigation and settlement issues affect Akynzeo?

The principal litigation risk is ANDA patent litigation under the Hatch-Waxman framework. Relevant disputes would likely concern:

• Validity of core combination claims.
• Infringement of formulation claims.
• Patent-term calculations.
• Section VIII label carve-outs.
• Induced infringement of CINV prevention methods.
• Launch timing under a settlement agreement.

No major public litigation outcome has established a broad commercial reset for Akynzeo comparable to the high-profile patent disputes affecting major oncology biologics. The main legal exposure remains prospective and tied to generic filings as the 2030 patent window approaches.

What geographic markets matter most for Akynzeo?

The United States is commercially important because it combines high oncology drug spending with substantial use of branded supportive-care products. Europe provides a broad multi-country market but introduces country-level pricing controls, health-technology assessment, hospital tenders, and parallel trade.

Key geographic variables include:

• U.S. Orange Book patent litigation and payer contracting.
• European centralized authorization and national reimbursement.
• Hospital procurement in the United Kingdom and other tender-driven markets.
• Local patent enforcement in major European states.
• Distribution economics in emerging oncology markets.

Regional rights can produce different loss-of-exclusivity dates and revenue curves. A U.S. generic launch would not automatically create simultaneous generic entry across Europe or other territories.

What manufacturing and intellectual-property barriers protect Akynzeo?

Manufacturing barriers are higher for the IV formulation than for the oral capsule. The IV product requires sterile production, validated stability, appropriate prodrug conversion, and regulatory control of injectable quality attributes.

The oral product is easier to manufacture in principle, but a generic applicant must still demonstrate bioequivalence and reproduce the required fixed-dose presentation. Formulation patents can raise development costs and force design-around work.

These barriers do not create permanent protection. They can delay entry, reduce the number of viable competitors, and support a period of limited generic supply after patent expiry.

Key Takeaways

• Akynzeo is a netupitant-palonosetron fixed-dose combination for prevention of acute and delayed CINV.
• Helsinn is the originator and principal rights holder; regional commercialization has involved licensing and collaboration partners, including Eisai in the United States.
• The FDA approved the oral product in 2014 and the IV formulation in 2018.
• The core U.S. patent estate has been associated with protection extending into the 2030 period, with later formulation and route-specific patents potentially extending beyond that date.
• Akynzeo has no biosimilar risk because it is a small molecule.
• Generic aprepitant, generic palonosetron, fosaprepitant, and separate-component regimens are the main commercial constraints.
• Standalone Akynzeo revenue is not publicly disclosed, preventing a verified annual sales trajectory.
• The oral product is likely to face earlier generic substitution than the IV formulation.
• The strongest commercial defense is the combination of fixed-dose convenience, route-specific formulation protection, and oncology-channel partnerships.
• The principal value inflection point is the approach of U.S. core patent expiry and any associated Paragraph IV litigation.

FAQs

Is Akynzeo more effective than aprepitant?

Akynzeo provides a fixed combination of netupitant and palonosetron, while aprepitant is an NK1 antagonist usually combined with a separate 5-HT3 antagonist. Comparative value depends on chemotherapy regimen, institutional protocol, patient risk, cost, and payer coverage.

Can generic companies copy Akynzeo as separate drugs?

Yes. Generic companies can market separate NK1 and 5-HT3 agents if they obtain the required approvals. That approach can compete with Akynzeo without reproducing the exact fixed-dose combination.

Will Akynzeo lose all value when the first patent expires?

No. Commercial erosion will depend on the number of approved generics, patent coverage for later formulations, payer substitution rules, physician adoption, and whether the IV product has separate remaining protection.

Does Akynzeo qualify for pediatric exclusivity?

Any pediatric exclusivity must be confirmed through current FDA product and Orange Book records. Pediatric exclusivity, if awarded, can add six months to applicable patent or regulatory protection.[5]

Is Akynzeo included in U.S. Medicare reimbursement?

Coverage depends on the administration setting, chemotherapy regimen, Part B or Part D treatment pathway, payer policy, and formulary status. Hospital outpatient and physician-office reimbursement can differ materially from retail pharmacy coverage.

References

1. U.S. Food and Drug Administration. (2014). Akynzeo prescribing information: Netupitant and palonosetron capsules. FDA.

2. U.S. Food and Drug Administration. (2018). Akynzeo prescribing information: Fosnetupitant and palonosetron for injection. FDA.

3. European Medicines Agency. (2015). Akynzeo: EPAR product information. EMA.

4. National Comprehensive Cancer Network. (2024). NCCN Clinical Practice Guidelines in Oncology: Antiemesis. NCCN.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

6. Eisai Co., Ltd. (2015). Annual report and pharmaceutical product information. Eisai.

DrugChatter Q&A for AKYNZEO

Eisai akynzeo patient product info?
Akynzeo iv reimbursement?
Helsinn akynzeo product info?
Helsinn akynzeo side effects?